-
"Friendly Words and Feelings" focuses on the humanistic slow variety show of oncologists! The first episode takes you into "patient-centric
Time of Update: 2022-10-03
Life is like four seasons There is spring and autumn fruits There is cold and summer Spring Nightingale, Summer looking at the stars, Enjoy the full moon in autumn and the first snow in winter Spendi
-
4 products have entered the clinic Eisai still decided to close H3 Biomedicine
Time of Update: 2022-10-01
4 products have entered the clinicEisai still decided to shut down H3 BiomedicineFounded in 2010, H3 Biomedicine focuses on discovering and developing precision cancer treatments using its integrated data science, human biology and precision chemistry discovery engine.
-
In this nearly 20 billion market, there have been a number of local pharmaceutical companies layout
Time of Update: 2022-10-01
In the domestic market, according to the website information of the State Food and Drug Administration, including Fuyuan Pharmaceutical, there are 3 manufacturers of paroxetine hydrochloride enteric-coated extended-release tablets that have been approved for listing in Chinese mainland.
-
Experts explain the quality and safety of pork: scientific nutrition and eat with confidence
Time of Update: 2022-09-29
Feed and feed additives are the material basis and technical guarantee of the modern pig industry, is a necessary measure to supplement pig nutrition, ensure product quality, but also the international general promotion of technology, China and the United States, Germany, Denmark and other pig breeding countries breeding technology, feed use, fertility cycle, pig weight, meat quality, product safety and other situations are basically consistent, in line with international standards and import and export trade guidelines requirements.
-
A large number of pharmaceutical companies are competing for the breast cancer drug market, and the price war is imminent
Time of Update: 2022-04-30
On March 6, the multinational pharmaceutical company Eli Lilly announced that its CDK4/6 inhibitor Abeccil (trade name: Weizhe) has been approved for early breast cancer indications in China.
-
Shangjian Bio-CD38/CD47 double antibody was approved for clinical use in the U.S
Time of Update: 2022-01-15
It is worth mentioning that, based on the BIMA double antibody platform, Sunkin Bio has also developed a number of "1+1>2" double antibody projects, two of which have been approved for clinical use .
-
"Growth hormone" quickly "out of the circle", Anke Bio-Human Growth Hormone Injection was approved to increase 2 indications
Time of Update: 2022-01-08
. The author was informed that, in addition to the above-mentioned breakthroughs in the human growth hormone injection field by Anke Biotech, Jichuan Pharmaceuticals recently issued an announcement stating that the company is expected to spend more than 2 billion yuan to obtain Tianjing Biotech through the License-in (licensed introduction) model.
-
18 new varieties passed the consistency evaluation, with 3 being the first
Time of Update: 2021-09-19
According to the incomplete statistics of the Medical Cloud Studio, there are currently 3,029 product regulations that have passed the consistency evaluation, and 353 product regulations have been evaluated by more than three (including three).
-
JNNP: A systematic review and meta-analysis of MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy
Time of Update: 2021-08-14
The work of this article conducts a meta-analysis and systematic review of existing relevant literature on laser interstitial hyperthermia, including postoperative adverse events and important surgical results (stratified by age), and expands the previous literature, etiology and follow-up (FU) time , Including studies of all ages and the etiology of DRE patients .
-
Kelun Class 1 new drugs are coming this year, 7 new drugs have been approved for clinical use
Time of Update: 2021-08-07
Kelun has been approved for clinical new drugs since 2021 Source: China Drug Clinical Trial Publicity Library of Meinenet The SKB337 injection, which is undergoing phase I clinical trials for advanced solid tumor indications, is a new generation of bispecific antibodies for tumor immune checkpoints.
-
Too many carcinogenic impurities
Time of Update: 2021-08-02
"The health benefits of quitting smoking exceed the theoretical potential carcinogenic risk that the nitrosamine impurities in Chantix may cause .
"Pfizer said in June that the company would suspend Chantix's global shipments due to nitrosamine impurities, and the drug is currently in short supply in the United States .
-
Pioneer Pharmaceuticals Prokalamide's Phase III clinical trial for the treatment of COVID-19 was approved by Brazil's ANVISA
Time of Update: 2021-06-22
announced that its Phase III clinical trial of Prokalamide for the treatment of male patients with mild and moderate new coronary disease has been formally approved by the Brazilian drug regulatory agency ANVISA on June 11, local time .
-
Approval | NMPA 2020 transcript: 1,096 innovative drugs were approved for clinical use, and 20 were approved for production
Time of Update: 2021-05-09
The report shows that in 2020, the State Food and Drug Administration will accept 587 imported clinical trial applications and 3397 applications for supplementary approval in provinces and cities; 1,096 innovative drugs have been approved for clinical use, and 20 innovative drugs have been approved for production, of which only 2 are biological products; 879 new drugs have been clinically approved, including 9 Chinese natural medicines.
-
Yangtze River Health: The State Food and Drug Administration agrees to change the holder of the marketing license for caspofungin acetate for injection
Time of Update: 2021-04-28
On March 18, the Yangtze River Health announced that the State Food and Drug Administration agreed that caspofungin acetate for injection (drug approval number: Sinopharm Zhunzi H202003001, Sinopharm Zhunzi H202003002, specifications 50mg, 70mg) drug marketing license holders "Borui Pharmaceutical (Suzhou) Co.
-
Fancy contenders for antibody drugs
Time of Update: 2021-03-27
▲The second TG-Bio immune technology conference in Bioogo 2021 ▲Currently, there are more than one hundred antibody drugs approved for marketing worldwide, involving 58 targets.
In addition, these small molecule inhibitors may not directly compete with antibody drugs with the same target.
